Integra Q2 2026: Revenue $418.8M (+0.8%), Adj EPS $0.56 vs $0.45; reaffirms FY adj EPS $2.40-$2.50

INTEGRA LIFESCIENCES HOLDINGS CORP

Q2 revenue $418.8M (+0.8% reported, +0.7% organic); GAAP EPS $0.06 vs -$6.31; adjusted EPS $0.56 vs $0.45.
Adjusted EBITDA $78.4M (18.7% of revenue) vs $71.2M (17.1%) in prior year.
Specialty Surgery revenue $309.3M (+1.6% organic); Tissue Reconstruction $109.5M (-2.0% organic).
Full-year reported revenue guidance narrowed to $1.654B-$1.695B (from $1.662B-$1.702B) due to FX; organic growth and adj EPS reaffirmed.
Braintree facility producing; SurgiMend relaunch on track for Q4 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.